norcantharidin has been researched along with Diabetic Glomerulosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q; Duan, SB; Hou, T; Li, J; Li, Y; Ling, GH; Liu, FY; Luo, JH; Peng, YM; Sun, L | 1 |
| Chen, Q; Duan, SB; Li, J; Li, Y; Ling, GH; Liu, FY; Luo, JH; Peng, YM; Sun, L; Wang, S | 1 |
2 other study(ies) available for norcantharidin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Norcantharidin attenuates tubulointerstitial fibrosis in rat models with diabetic nephropathy.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Calcineurin; Collagen Type IV; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Evaluation, Preclinical; Fibronectins; Fibrosis; Kidney; Male; Nephritis, Interstitial; Proteinuria; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1 | 2011 |
Norcantharidin inhibits the expression of extracellular matrix and TGF-β1 in HK-2 cells induced by high glucose independent of calcineurin signal pathway.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Calcineurin; Cell Line; Cell Proliferation; Collagen Type IV; Diabetic Nephropathies; Drug Evaluation, Preclinical; Epithelial Cells; Extracellular Matrix; Fibronectins; Glucose; Humans; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta1 | 2011 |